News | July 23, 2014

Young Women With Heart Attacks Continue to Fare Worse Than Men

heart attacks, women's health
While awareness campaigns may be getting women to go to the hospital more quickly during a heart-attack, a new look at hospital data shows women have longer hospital stays and are more likely than men to die in the hospital after a heart attack. In the study published online in the Journal of the American College of Cardiology, researchers from Yale School of Medicine analyzed 230,684 hospitalizations for heart attack in patients age 30 to 54 from a total of 1.1 million hospitalizations reported in a national database from 2001 to 2010. The study found that heart attack hospitalization rates for patients under age 55 have not declined as quickly as they have for Medicare-age patients, which have seen a 20 percent drop. 
 
“This trend suggests we need to raise awareness of the importance of controlling cardiovascular risk factors like diabetes, high blood pressure and smoking in younger patients,” said lead author Aakriti Gupta, M.D.
 
All patient groups in the study saw increases in coexisting medical conditions including high blood pressure and diabetes. Men were more likely to have high cholesterol while women, especially black women, were more likely to also have hypertension, diabetes and heart failure. The authors concluded that younger women may benefit from more aggressive control of modifiable cardiovascular risk factors, including early identification and treatment of high blood pressure, high cholesterol, obesity, smoking and diabetes.
 
“Younger women are a vulnerable yet understudied group with worse cardiac risk profiles and worse outcomes after a heart attack as compared with younger men,” Gupta said. 
 
For more information: www.cardiosource.org/acc

Related Content

Biotronik Studies Demonstrate Efficacy of Minimizing Metal Burden in SFA Therapy
News | Stents Bare Metal| September 22, 2017
Physicians demonstrated that reducing metal burden in superficial femoral artery (SFA) therapy could effectively reduce...
Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017
News | Heart Failure| September 21, 2017
MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study...
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
NIAID Scientists Illuminate Mechanism of Increased Cardiovascular Risks With HIV
News | Cardiac Diagnostics| September 14, 2017
September 14, 2017 — Scientists at the National Institutes of Health have expanded the understanding of how chronic i
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Overlay Init